Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,
Show Sustained Improvements in Clinical Efficacy Endpoints
and No Treatment Interruptions for Low Ejection Fraction
Commercial Readiness Activities Leverage Insights from Market Research
to Inform Market Segmentation and Patient-Centric Strategies
New Pre-Clinical Data for CK-586 Shows Improved Diastolic Function
and Reduced Cardiac Fibrosis in Animal Model of HFpEF; Phase 1 Study Ongoing
“Cytokinetics is advancing plans to build a specialty cardiology franchise anchored by aficamten. We believe we have a unique opportunity to address the multiple manifestations of cardiac hypercontractility with both our late-stage programs and our earlier-stage pipeline,” said
New Long-Term Data from FOREST-HCM Support Development Program for Aficamten
The company plans to present today new long-term efficacy and safety data from FOREST-HCM, an open-label extension clinical study of aficamten. More than 200 patients have been enrolled in FOREST-HCM to date and 143 patients were available for this analysis. Of the 94 patients who had completed the titration period (by Week 12), approximately two-thirds are receiving the 15 mg or 20 mg doses of aficamten. During the titration period, there have been no treatment-related instances of left ventricular ejection fraction (LVEF) <50%. During the maintenance phase, there have been no instances of LVEF <40%, which would require dose interruption, and only three instances of LVEF <50% that required a dose down-titration. Therefore, of the 579 monitoring echocardiograms completed during the maintenance phase of treatment, 99.5% of them did not result in a dose reduction.
Additionally, after prolonged treatment for more than two years in some patients, the mean resting left ventricular outflow tract gradients (LVOT-G) and mean Valsalva LVOT-Gs remained reduced and below the diagnostic threshold for obstructive HCM (oHCM). Patients also experienced sustained reductions in cardiac biomarkers and improved symptoms. The KCCQ increased by ≥5 points in 71% of patients, 30% of whom had an improvement of ≥10 points. Approximately half of patients were asymptomatic at one year by NYHA Functional Class assessment, and 80% of patients improved by one or more Functional Class at every visit after starting treatment with aficamten. Of patients eligible for septal reduction therapy (SRT) at baseline, 90% were no longer SRT-eligible at the time of this analysis. Aficamten has been generally well-tolerated, with 60% of patients experiencing at least one treatment emergent adverse event (TEAE) but no treatment-related serious adverse events (SAEs) as assessed by investigators, and no patient deaths.
Preparing for Commercial Readiness for the Potential Approval and Launch of Aficamten
Expanding Clinical Research with CK-586 for the Potential Treatment of HFpEF
The company plans to present today new pre-clinical data for CK-586, a cardiac myosin inhibitor, which is currently the subject of an ongoing Phase 1 study and is in development for the potential treatment of patients with HFpEF. These preclinical data show improved diastolic function and reduced cardiac fibrosis in an animal model of HFpEF. Cytokinetics’ management will also discuss the rationale for the development of CK-586 in a defined subset of patients with HFpEF characterized by hypercontractility resembling nHCM.
At today’s Investor & Analyst Day, a panel of leading physician experts in the treatment of HCM will discuss perspectives on the evolving HCM landscape. Panelists include:
Theodore Abraham, M.D., FACC, FASE, Meyer Friedman Distinguished Professor of Medicine, Division of Cardiology, University of California, San Francisco; Co-director, UCSF HCM Center of Excellence; Director, UCSF Adult Cardiac Echocardiography Laboratory Caroline Coats, Ph.D., Clinical Senior Lecturer, School of Cardiovascular & Metabolic Health, University of Glasgow Carolyn Ho, M.D., Associate Professor, Harvard Medical School, Medical Director of the Cardiovascular Genetics Center
In addition, a patient living with HCM will share her experience and perspectives.
Access to Virtual Event
Interested parties must register online at https://cytokinetics-new-horizons-in-hypercontractility.open-exchange.net/. Registered attendees may access the virtual event platform by visiting the Investor & Media section of the
About Aficamten and the Broad Phase 3 Clinical Trials Program
Aficamten is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties and as may translate into next-in-class potential in clinical development. Aficamten was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with hypertrophic cardiomyopathy (HCM). In preclinical models, aficamten reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state.
The development program for aficamten is assessing its potential as a treatment that improves exercise capacity and relieves symptoms in patients with HCM as well as its potential long-term effects on cardiac structure and function. Aficamten is currently the subject of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a pivotal Phase 3 clinical trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, and ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), a pivotal Phase 3 clinical trial in patients with symptomatic non-obstructive HCM. Results from SEQUOIA-HCM are expected by the end of 2023. Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart’s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed in the
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten, CK-586 or any of our other drug candidates, our ability to announce the results of SEQUOIA-HCM by the end of 2023, our ability to submit or obtain approval of a future new drug application or other marketing authorization application for aficamten in oHCM or nHCM or commercially launch aficamten in
CYTOKINETICS® and the
Senior Vice President, Corporate Communications, Investor Relations
- CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575.
Symphony Health2016-2021 Patient Claims Data DoF.
- Maron MS, Hellawell JL, Lucove JC,
Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
- Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the
American College of Cardiology Foundation/American Heart Association Task Forceon practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
- Hong Y, Su WW,
Li X. Riskfactors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21.
Source: Cytokinetics, Incorporated